The oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, today announces its financial results for the six months ended 31 December 2020. Total income was up 12% to £363k. Operating losses of £132k were just £14k greater than those of the comparable prior period despite a significant increase in marketing activities. The Company finished the half with a strong balance sheet w ....
01 Mar 2021
Modelling and simulation business trading well as attention turns to commercial asset in personalised medecine
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Modelling and simulation business trading well as attention turns to commercial asset in personalised medecine
Physiomics Plc (PYC:LON) | 1.4 0 0.0% | Mkt Cap: 1.83m
- Published:
01 Mar 2021 -
Author:
Derren Nathan -
Pages:
7
The oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, today announces its financial results for the six months ended 31 December 2020. Total income was up 12% to £363k. Operating losses of £132k were just £14k greater than those of the comparable prior period despite a significant increase in marketing activities. The Company finished the half with a strong balance sheet w ....